Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Mechanism of Action
Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation.
Dosage Overview
Dose Range
500 mcg – 12 mg
Route
subcutaneous
Frequency
Weekly
Cycle Length
12–52 weeks
Reconstitution
Typical Dosage (Research)
Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials.
Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved.
Considerations for Men & Women
Women: As a triple-agonist (GLP-1/GIP/glucagon), pregnancy contraindications apply — discontinue before planned conception. Potential oral contraceptive interactions due to gastric emptying effects. Early trial data shows similar weight loss efficacy in both sexes.
Men: Early clinical data suggests potential testosterone improvements secondary to weight loss. No sex-specific dosing differences in clinical trials to date.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 5,000 mcg/ml
Volume to inject: 0.10 ml
Syringe units (U-100): 10.0 units
Pre-filled with Retatrutide defaults. Adjust values as needed.
Side Effects & Risks
Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity.
Still investigational - full safety profile being established. Expected similar warnings to GLP-1 class regarding thyroid, pancreatitis, and gallbladder.
Who Uses Retatrutide
Currently only available to clinical trial participants. Expected approval would target severe obesity and metabolic syndrome.
Similar Peptides
View All Alternatives →Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.